Small French biotech has big ideas in NASH

28 March 2019

Ringing the opening bell at the Nasdaq stock exchange on Wednesday, Lille, France-based biotech Genfit (EPA: GNFT) celebrated its listing in New York, raising 130 million euros ($146 million) in the process.

Markets welcomed the firm’s listing in Times Square, boosting the share price 10% in its first full day of trading. Shares in the French biotech firm, which also has offices in Massachusetts, USA, have been bought and sold in Paris since 2006.

Genfit is focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases. The firm plans to spend around 40 million euros of the new money on late stage testing for its lead candidate elafibranor, a possible treatment for non-alcoholic steatohepatitis (NASH).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK